Compound Deep Dive
Retatrutide: The Triple Agonist Explained — What Early Reports Show
8 min read3 peptides covered
Early analysis of Retatrutide — the first GIP/GLP-1/Glucagon triple agonist with potentially superior weight loss.
Is Retatrutide better than Tirzepatide?
Early data suggests Retatrutide may produce even greater weight loss than Tirzepatide (24% vs 21% at 48 weeks in trials). As a triple agonist (GIP/GLP-1/Glucagon), it has additional metabolic effects. However, it's still in clinical trials and community data is limited.